Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M800021200 on March 31, 2008

J. Biol. Chem., Vol. 283, Issue 22, 15319-15327, May 30, 2008
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/22/15319    most recent
M800021200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Byon, C. H.
Right arrow Articles by Chen, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byon, C. H.
Right arrow Articles by Chen, Y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Oxidative Stress Induces Vascular Calcification through Modulation of the Osteogenic Transcription Factor Runx2 by AKT Signaling*

Chang Hyun Byon{ddagger}, Amjad Javed§1, Qun Dai||, John C. Kappes||**{ddagger}{ddagger}2, Thomas L. Clemens**, Victor M. Darley-Usmar**§§3, Jay M. McDonald**{ddagger}{ddagger}, and Yabing Chen**§§4

From the Departments of {ddagger}Cell Biology, ||Medicine, and **Pathology, §Institute of Oral Research, Center for Metabolic Bone Disease, and §§Center for Free Radical Biology, University of Alabama at Birmingham and {ddagger}{ddagger}Veterans Affairs Medical Center Research Service, Birmingham, Alabama 35294

Received for publication, January 2, 2008 , and in revised form, March 11, 2008.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Oxidative stress plays a critical role in the pathogenesis of atherosclerosis including the formation of lipid laden macrophages and the development of inflammation. However, oxidative stress-induced molecular signaling that regulates the development of vascular calcification has not been investigated in depth. Osteogenic differentiation of vascular smooth muscle cells (VSMC) is critical in the development of calcification in atherosclerotic lesions. An important contributor to oxidative stress in atherosclerotic lesions is the formation of hydrogen peroxide from diverse sources in vascular cells. In this study we defined molecular signaling that is operative in the H2O2-induced VSMC calcification. We found that H2O2 promotes a phenotypic switch of VSMC from contractile to osteogenic phenotype. This response was associated with an increased expression and transactivity of Runx2, a key transcription factor for osteogenic differentiation. The essential role of Runx2 in oxidative stress-induced VSMC calcification was further confirmed by Runx2 depletion and overexpression. Inhibition of Runx2 using short hairpin RNA blocked VSMC calcification, and adenovirus-mediated overexpression of Runx2 alone induced VSMC calcification. Inhibition of H2O2-activated AKT signaling blocked VSMC calcification and Runx2 induction concurrently. This blockage did not cause VSMC apoptosis. Taken together, our data demonstrate a critical role for AKT-mediated induction of Runx2 in oxidative stress-induced VSMC calcification.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Atherosclerosis is characterized by the presence of atherosclerotic lesions in the arterial intima that leads to narrowing of the vessel lumen. Vascular calcification, the presence of calcium deposits in the vessel wall, is a feature of advanced atherosclerosis and reduces elasticity and compliance of the vessel wall (1). Hence, the extent of calcification is a key risk factor in the pathogenesis of the disease. Several cell types, such as endothelium, monocytes, and vascular smooth muscle cells (VSMC),5 are involved in different stages of lesion development. VSMC contribute to the development of atherosclerotic lesions through increased migration, proliferation, secretion of matrix components, osteogenic differentiation, and the associated calcification (1). During this process, the differentiated VSMC undergo de-differentiation, and subsequently osteogenic transition that results in vascular calcification (2).

Many factors that have been linked to an increased prevalence of vascular calcification are associated with elevated oxidative stress, including hypercholesterolemia, hypertension, diabetes mellitus, and dialysis-dependent end stage renal disease (3-6). Pro-oxidant events in atherosclerosis include the production of reactive oxygen species (ROS) and nitrogen species by vascular cells (7). Of particular interest is hydrogen peroxide (H2O2), which is a cell-permeable ROS that has emerged as a key mediator of intracellular signaling (8-10). H2O2 is produced in vascular cells by multiple enzymatic systems including vascular NAD(P)H oxidases, mitochondria, xanthine oxidase, and uncoupled endothelial nitric-oxide synthase (11-13). Under normal conditions constitutive oxidase activities and endogenous scavenger systems, including catalase and glutathi-one peroxidases, maintain steady-state H2O2 levels in vascular tissue (10). Upon stimulation, these oxidases in the endothelium, media, and adventitia can produce H2O2 and contribute to increased exposure of VSMC to this oxidant (10, 14).

VSMC exhibit an extraordinary capacity to undergo phenotypic change during development in cultures and in association with diseases (15). Emerging evidence supports the concept that vascular calcification, like mineralization of bones and teeth, is a cell-regulated process (16). Osteogenic differentiation of VSMC is characterized by the expression of multiple bone-related molecules including alkaline phosphatase (ALP), type I collagen (Col I) and osteocalcin (OC) and the formation of mineralized bone-like structures (17). During osteoblast differentiation these molecules are expressed at different phases and reflect different aspects of osteoblast function and bone formation. ALP and Col I are early markers, and OC is a late marker (18-20). Runx2 is a key transcription factor that regulates osteoblast (21) and chondrocyte differentiation (22). Runx2 has been shown to induce ALP activity and the expression of bone matrix protein genes, including OC, Col I, bone sialoprotein, and osteopontin, as well as mineralization in immature mesenchymal cells and osteoblastic cells in vitro (21, 23). Runx2 expression has been identified in atherosclerotic calcified human vascular tissue specimens (24-26) and in calcifying aortic smooth muscle cells in mice (16) but not in normal vessels. Furthermore, increased expression of Runx2 is associated with VSMC calcification in vitro (16, 27, 28), supporting a role for Runx2 in vascular calcification. However, the potential link between Runx2 regulation and oxidative stress-induced vascular calcification has not been examined.

In the present study we hypothesized that H2O2 regulates VSMC calcification through modulation of the activity and expression of Runx2. Using a cell culture model we found that Runx2 is essential for H2O2-induced VSMC calcification. This oxidative stress-activated Runx2 response is in turn dependent on the activation of AKT. Taken together these studies demonstrate for the first time key steps in the redox cell signaling pathways that lead to VSMC calcification and the essential role of Runx2 in this process.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
VSMC Culture—Primary VSMC used in the present studies were isolated from the aortas of C57BL/6 mice (29, 30) and confirmed by flow cytometry with the use of smooth muscle specific {alpha}-actin antibody ({alpha}-SMA). All experiments were performed with VSMC at passages 3-5.

In Vitro Calcification—Calcification of VSMC was induced by the addition of H2O2 in osteogenic media containing 0.25 mML-ascorbic acid, 10 mM β-glycerophosphate, and 10-8 M dexamethasone (Sigma-Aldrich) for 3 weeks. Alternatively, cells were incubated with glucose oxidase (2 or 5 milliunits/ml) for 12 h with media changes every 2-3 days.

Mineralization was determined by von Kossa staining as previously described (31). Briefly, cells were fixed by 2% paraformaldehyde in phosphate-buffered saline for 15 min and washed with deionized water 3 times. After adding 5% silver nitrate (Sigma-Aldrich) in deionized water, plates were placed on aluminum foil under a 60-watt white lamp until the calcium phosphate turned black. Plates were washed with deionized water 3 times, and 5% sodium thiosulfate (Sigma-Aldrich) was added for 5 min to remove unreacted silver. Mineralized nodules were quantified by attaching the culture dish to a grid ruled in 2-mm squares and viewing the cultures through an inverted microscope at a magnification of 40x in five randomly selected fields as described (32).

The roles of mitogen-activated protein kinase kinase, phospholipase C (PLC), and phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathways in oxidative stress-induced VSMC calcification were determined with inhibitors, including PD98059, U73122 [GenBank] , LY294002, and AKT Inhibitor IV (Calbiochem).

Total Calcium Measurement—Cells were lysed with 0.5 N HCl by shaking overnight at room temperature. Total calcium in the cell lysates was determined by Arsenazo III (Sigma-Aldrich).

Reverse Transcriptase-Polymerase Chain Reaction and Real-time PCR Analysis—The effect of oxidative stress on the expression of bone-related and smooth muscle-specific gene markers was determined by RT-PCR and real-time PCR. Total RNA was isolated from VSMC using Trizol (Invitrogen) and reverse-transcribed into cDNA. PCR were performed using specific primers for murine ALP (33), Col IA1 (34), OC (35), Runx2 (36), {alpha}-SMA (37), SM22{alpha} (37), myocardin (38), serum response factor (SRF) (39), and GAPDH as control (40). SYBR Green-based real time PCR was performed in a 96-well plate format using SYBR Premix Ex Taq (TaKaRa) on an iCycler Thermal Cycler (Bio-Rad).

Western Blot Analysis—VSMC cell extracts were prepared, and protein concentration was measured as described previously (29, 30). Western blot analyses were performed with the use of specific antibodies for extracellular-regulated kinase (ERK), p-ERK, PLC{gamma}, p-PLC{gamma}, AKT, p-AKT (Cell Signaling), and Runx2 (Calbiochem) and detected with a Western blot chemiluminescence detection kit (Millipore).

Detection of Runx2 Transactivity—Runx2 transactivity was determined by a Dual-Luciferase Reporter assay with the use of p6xRunxLuc, a luciferase reporter construct containing six Runx binding elements in the promoter region (41). VSMC were seeded in 6-well plates and transiently transfected with 1 µg of p6xRunxLuc using FuGENE 6 (Roche Applied Science). A plasmid encoding Renilla luciferase gene downstream of a minimal SV40 promoter was used to normalize for transfection efficiency (42). 24 h after transfection VSMC were washed and treated with 0.4 mM H2O2 for an additional 24 or 48 h. Luciferase activities were determined with the Dual-Luciferase assay kit (Promega).

Lentiviral shRNA Transduction for VSMC—Five lentiviral vectors expressing a 21-nucleotide Runx2 short hairpin RNA (shRNA) were purchased from Open Biosystems. The expression of shRNA is driven by a human U6 promoter followed by puromycin driven by human phosphoglycerate kinase promoter. Each vector was packed into lentivirus-like particles pseudotyped with the vesicular stomatitis virus glycoprotein as previously described (43). The position of each of the core 21-nucleotide sequences targeted nucleotides was 4765-4785 (#1), 1664-1684 (#2), 1231-1251 (#3), 1757-1777 (#4), and 131-151 (#5), of the murine Runx2 gene (GenBankTM accession number NM_009820 [GenBank] ). Blast search was performed using the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) data base to ensure that the shRNA construct only targeted murine Runx2. Transduction was performed by incubating VSMC with recombinant lentiviral vector in growth media supplemented with 10 µg/ml diethylaminoethyl (DEAE)-dextran. After 24 h cells were washed with phosphate-buffered saline and cultured in growth media containing 5 µg/ml puromycin for 2 weeks to select stable expression transfectants, which were further cultured in osteogenic media for 3 weeks to induce calcification.


Figure 1
View larger version (43K):
[in this window]
[in a new window]

  		FIGURE 1.
Hydrogen peroxide induces VSMC calcification. A, VSMC were exposed to 0.1 and 0.4 mM H2O2 or glucose oxidase (final concentration to 2 and 5 milliunits/ml) in osteogenic media for 3 weeks with media change every 2 or 3 days. In vitro VSMC calcification was determined by von Kossa staining. Representative images of stained dishes (upper) and microscopic views (x40, lower) from four independent experiments are shown. B, effect of H2O2 or glucose oxidase on a number of mineralized nodules formed by VSMC incubated for 3 weeks in osteogenic media was quantified by counting nodules in each stained culture dish. The number of nodules/cm2 was determined by taking the means of 5 individual counts and is represented as -fold increase compared with control (*, p < 0.001, n = 4). C, total calcium levels were determined in VSMC exposed to 0.3 and 0.4 mM H2O2 in osteogenic media for 1 or 2 weeks by Arsenazo III. Results from two independent experiments performed in duplicate are shown.

 
Adenovirus-mediated Transduction of Runx2—Adenovirus encoding murine wild-type Runx2 (Ad-Runx2) was kindly provided by Dr. Renny Franceschi (University of Michigan) (44), and transduction of adenovirus into VSMC was performed as we previously described (30). Briefly, VSMC grown in six-well plates were infected with Ad-Runx2 at different multiplicities of infection for 2 h in serum-free media and 16 h in serum-containing media. Subsequently, cells were cultured in osteogenic media for 3 weeks.

Assessment of Apoptosis—To examine the effect of oxidative stress or AKT inhibition on VSMC apoptosis, annexin V and propidium iodine staining were performed with the annexin V-FITC apoptosis detection kit (BD Biosciences) as we previously described (45). Apoptosis was reported as the percentage of annexin V-positive and propidium iodine-negative cells.

Statistical Analysis—Results are expressed as the means ± S.D. Differences between two groups were identified with Student's t tests. Significance was defined as p < 0.05.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Hydrogen Peroxide Induces VSMC Calcification—First, we examined the effect of H2O2 added directly to the cells or generated at a low flux from the enzyme glucose oxidase (46) on in vitro calcification of VSMC. We found that glucose oxidase or H2O2 at the non-toxic concentrations of 0.1-0.4 mM induced VSMC calcification in concentration-dependent manners, as indicated by the black granule formation after von Kossa staining (Fig. 1, A and B) or total calcium levels (Fig. 1C). Taken together, these results establish an in vitro oxidative stress-induced differentiation and calcification of VSMC model in vitro.

Oxidative Stress Induces the Expression of Bone Markers and Down-regulates Smooth Muscle Cell Markers—Accumulating evidence supports the concept that vascular calcification resembles the process of osteogenesis (47, 48). Therefore, we determined the effect of oxidative stress on osteogenic transdifferentiation of VSMC and examined the expression of bone and VSMC markers.

The expression of bone markers ALP, Col IA1, and OC was dramatically increased in H2O2-treated cultures (Fig. 2A). In contrast, the expression of VSMC markers {alpha}-SMA and SM22{alpha} decreased gradually during the osteogenic differentiation of VSMC (Fig. 2A). Real-time PCR was performed, which confirmed increased expression of ALP, OC, and Col IA1 after VSMC were exposed to 0.4 mM H2O2 for 10 days (fold increase: ALP = 8.7 ± 1.2, OC = 5.3 ± 1.4, and Col IA1 = 6.6 ± 0.9, compared with control, Fig. 2B). On the other hand, the expression of {alpha}-SMA was decreased by 79% and SM22{alpha} by 83% after VSMC were exposed to 0.4 mM H2O2 for 10 days (Fig. 2C). These results demonstrated that induction of bone markers and loss of smooth muscle cell-specific phenotypes is associated with oxidative stress-induced VSMC calcification.

Oxidative Stress Increases Runx2 Expression and Transactivity in VSMC—The transcription factor Runx2 is a key regulator of osteoblast differentiation which regulates the expression of many bone markers (21). Thus, we determined whether H2O2 affects the expression and transactivity of Runx2 during VSMC calcification.

We found that H2O2 increased the expression of the Runx2 transcript (Fig. 3A). This result was further confirmed by quantitative real-time PCR, demonstrating a 4.5-fold increase in Runx2 mRNA after VSMC were exposed to H2O2 for 10 days (Fig. 3B). To test if the H2O2-induced increase in Runx2 message was translated to the protein level, Western blot analysis was performed. Expression of Runx2 protein was increased in VSMC exposed to H2O2 for 2 and 3 weeks (Fig. 3C). To determine whether H2O2-induced Runx2 protein was transcriptionally active, a luciferase reporter assay was performed. A multimerized Runx2 promoter reporter was transiently transfected into VSMC, which was subsequently stimulated with H2O2 (Fig. 3D). A 2-fold increase in Runx2 transactivity was observed at 24 and 48 h after VSMC was exposed to H2O2. These results suggest that H2O2-increased Runx2 expression and transactivity may contribute to oxidative stress-induced VSMC calcification.


Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 2.
Oxidative stress induces the expression of bone markers and down-regulates smooth muscle cell markers. A, expression of bone-related molecules ALP, OC, and Col IA1 and VSMC markers {alpha}-SMA and SM22{alpha} during VSMC calcification was determined by RT-PCR. VSMC were exposed to 0.4 mM H2O2 in osteogenic media for up to 11 days. Representative RT-PCR pictures of three independent experiments are shown. Real-time PCR for bone-related molecules (B) and VSMC markers (C) was performed in VSMC exposed to 0.4 mM H2O2 in osteogenic media for 10 days. Results from three independent experiments performed in duplicate are shown (*, p < 0.001 compared with controls).

 
Down-regulation of Runx2 Inhibits VSMC Calcification—For a mechanistic understanding of H2O2-induced Runx2 expression and VSMC calcification, we employed shRNA-containing lentiviral vectors to knock down the expression of Runx2. Five lentiviral vectors from Open Biosystems were tested, and the one that knocked down Runx2 protein most effectively was selected for further studies. As expected, VSMC infected with a control virus (lenti-GFP) underwent calcification when treated with H2O2 (Fig. 4A). By contrast, H2O2-induced calcification was inhibited when Runx2 was knocked down (Fig. 4A). We confirmed that the expression of Runx2 was inhibited by shRNA (Fig. 4B), and inhibition of calcification was correlated with reduced levels of Runx2 (Fig. 4, A and B). Thus, our data support an essential direct role of Runx2 in oxidative stress-induced VSMC calcification.

To determine whether Runx2 knockdown may affect H2O2-induced expression of bone-related molecules and down-regulation of VSMC markers, we compared the expression of those marker genes in control and Runx2 knockdown VSMC. Increased expression of ALP and Col IA1 by H2O2 was totally blocked in Runx2 knockdown VSMC (Fig. 4B). Real-time PCR confirmed the down-regulation of bone-related molecules in Runx2 knockdown VSMC exposed to H2O2 (Fig. 4C). We found that the expression of VSMC transcription factors myocardin and SRF was decreased after VSMC were exposed to H2O2 for 2 weeks (Fig. 4B). The inhibitory effect of H2O2 on the expression of transcription factors was not restored in Runx2 knockdown cells, which was confirmed by real-time PCR analysis (Fig. 4D). Furthermore, H2O2-inhibited expression of SMC marker genes was not totally rescued by Runx2 knockdown, suggesting that additional signaling pathways independent of Runx2 may regulate H2O2-inhibited expression VSMC markers.

Overexpression of Runx2 Increases VSMC Calcification—To verify if that Runx2 alone is sufficient to induce VSMC calcification, we overexpressed Runx2 in VSMC by adenovirus carrying the Runx2 gene (44). Western blot analysis revealed that control VSMC expressed barely detectable levels of Runx2 protein. In contrast, Ad-Runx2-infected cells showed a concentration-dependent increase in Runx2 levels (Fig. 5A). VSMC calcification was enhanced by Ad-Runx2 with maximal induction of mineralization observed at a 200 multiplicity of infection (Fig. 5B), whereas VSMC calcification was not affected in VSMC transduced with control virus (Ad-GFP). These results demonstrate that Runx2 is an essential and sufficient player in regulating oxidative stress-induced VSMC calcification.

PI3K/AKT Signaling Mediates Oxidative Stress-induced Runx2 Activation and VSMC Calcification—H2O2 has been implicated in the activation of many downstream signaling pathways, including PI3K, ERK, and AKT, in a variety of cells (8, 9). Thus, we determined whether activation of these signaling pathways by H2O2 was required for VSMC calcification. We found that H2O2 stimulated rapid activation of ERK, AKT, and PLC{gamma}, an important mediator for intracellular calcium signaling, with maximal induction at 15 min (Fig. 6A). Inhibition of MAPK kinase by PD98059 (0.1-100 µM) or PLC by U73122 [GenBank] (0.1-10 µM) did not affect H2O2-induced VSMC calcification (data not shown). However, inhibition of AKT signaling by LY294002 and AKT inhibitor IV potently prevented oxidative stress-induced VSMC calcification (Fig. 6B). The effects of these inhibitors on AKT activation was confirmed by Western blot analysis, demonstrating inhibition of p-AKT in VSMC exposed to these inhibitors (Fig. 6B). Furthermore, we found that increased expression of Runx2, ALP, and Col IA1 under oxidative stress was blocked by AKT inhibition, whereas H2O2-induced down-regulation of {alpha}-SMA was not restored by AKT inhibition (Fig. 6C). Inhibition of oxidative stress-induced Runx2 transactivity was also demonstrated with AKT inhibitor IV (Fig. 6D). In addition, the effect of oxidative stress or AKT inhibition on VSMC calcification was not due to increased apoptosis (Fig. 6E). In summary, our data demonstrate that Runx2 is an integral component of oxidative stress-induced calcification of VSMC, and AKT signaling plays an important role in mediating oxidative stress-induced Runx2 up-regulation and VSMC calcification.


Figure 3
View larger version (31K):
[in this window]
[in a new window]

  		FIGURE 3.
Oxidative stress increases the expression and transactivity of Runx2 in VSMC. A, expression of Runx2 mRNA in VSMC exposed to H2O2 at 0.3 and 0.4 mM in osteogenic media was determined by RT-PCR. B, real-time PCR was performed in VSMC exposed to 0.4 mM H2O2 in osteogenic media for 10 days. Results from three independent experiments performed in duplicate are shown (*, p < 0.001 compared with control). C, expression of Runx2 protein in VSMC exposed to H2O2 at 0.3 and 0.4 mM in osteogenic media was determined by Western blot analysis. D, Runx2 transactivity in VSMC under oxidative stress was determined with a luciferase reporter. VSMC were transiently co-transfected with p6xRunxLuc and a plasmid expressing Renilla luciferase as an internal control reporter. Transfected cells were exposed to 0.4 mM H2O2 for 24 or 48 h, and the reporter luciferase activities were determined and normalized to the Renilla luciferase activity using Dual-Luciferase Reporter assay system. Results from three independent experiments performed in duplicate are shown (*, p < 0.005 for 48 h compared with control).

 


Figure 4
View larger version (39K):
[in this window]
[in a new window]

  		FIGURE 4.
Down-regulation of Runx2 inhibits VSMC calcification but shows no effect on oxidative stress-inhibited smooth muscle markers. A, VSMC were infected with vesicular stomatitis virus glycoprotein pseudotyped lentiviral vector encoding GFP or shRNA against Runx2 (shRunx2) and selected in puromycin for 2 weeks. Subsequently, cells were exposed to 0.4 mM H2O2 in osteogenic media for 3 weeks. In vitro calcification was determined by von Kossa staining. Representative images of two independent experiments are shown: stained dishes (upper) and microscopic views (x40, lower). B, knockdown of Runx2 protein expression in shRunx2-infected VSMC exposed to 0.4 mM H2O2 in osteogenic media for 3 weeks was determined by Western blot analysis (upper two rows). Expression of bone-related molecules ALP and Col IA1 and VSMC markers {alpha}-SMA, SM22{alpha}, myocardin, and SRF in VSMC infected with shRunx2 exposed to 0.4 mM H2O2 in osteogenic media for 2 weeks was determined by RT-PCR. Representative RT-PCR pictures of two independent experiments are shown. Real-time PCR for bone-related molecules (C) and VSMC markers (D) was performed in shRunx2-infected VSMC exposed to 0.4 mM H2O2 in osteogenic media for 2 weeks.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Increased vascular formation of H2O2, a highly diffusible ROS capable of initiating redox cell signaling, is known to play an important role in the pathogenesis of atherosclerosis (14). In the present study we demonstrated that H2O2, at concentrations of 0.1 to 0.4 mM, induces osteogenic differentiation and calcification of VSMC in a concentration dependent manner. These levels of H2O2 are consistent with the amounts generated by the increased levels of oxidant enzymes associated with atherosclerosis including xanthine oxidase and NAD(P)H oxidases (14). Furthermore, previous reports have shown that the viability of VSMC is not affected by H2O2 concentrations up to 800 µM (49). Here we confirmed that the effect of H2O2 on VSMC calcification is not due to VSMC apoptosis (Fig. 6E), although VSMC apoptosis has been implicated in vascular calcification in atherosclerotic lesions (50) and in the initiation and propagation of the calcification of calcifying vascular cells induced by BMP2 (1).

Our observation that oxidative stress-induced VSMC calcification is consistent with the previous reports that H2O2 induces osteogenic differentiation of calcifying vascular cells (51, 52) and odontoblasts (53). A recent study demonstrated that increased ROS generation, particularly H2O2, is predominately located around calcifying foci, which potentiates aortic valve calcification progression (54). By contrast, H2O2 has been shown to have adverse effects on osteogenic differentiation of MC3T3-E1 cells, a pre-osteoblastic cell line (53), and primary bone marrow stromal cells and calvarial osteoblast precursors (55). Therefore, the effects of H2O2 on osteogenic differentiation appear to be cell type-dependent. Interestingly, clinical studies have found that increased arterial calcification correlates with an increase in osteoporosis (56), a disease with increased bone loss. It is not known whether the reciprocal effects of oxidative stress on VSMC calcification and osteoblast differentiation are involved in the development of vascular calcification and osteoporosis simultaneously. Thus, further investigations are warranted to elucidate the redox-dependent distinct signaling cascades that regulate VSMC calcification and osteoblast differentiation.


Figure 5
View larger version (111K):
[in this window]
[in a new window]

  		FIGURE 5.
Overexpression of Runx2 increases VSMC calcification. A, VSMC were infected with Ad-Runx2, and the expression of Runx2 protein in Ad-Runx2-transduced cells cultured in osteogenic media for 1 week was determined by Western blot analysis. Representative blot of two independent experiments is shown. MOI, multiplicity of infection. B, VSMC were transduced with Ad-Runx2 or control virus (Ad-GFP) and cultured in osteogenic media for 3 weeks. In vitro calcification was determined by von Kossa staining. Representative images of two independent experiments are shown: stained dishes (upper) and microscopic views (x40, lower).

 
In atherosclerosis, VSMC have the ability to undergo reversible differentiation into cells with features of other mesenchymal lineages, such as osteoblasts, chondrocytes, and adipocytes (15, 57, 58). We found that H2O2-induced VSMC calcification was associated with down-regulation of VSMC-specific markers and induction of bone markers, including ALP, OC, and Col I (Fig. 2), indicating a phenotypic change of VSMC into osteoblast-like cells.

Increased expression of bone markers has been documented in osteogenic differentiation of VSMC induced by acetylated low density lipoprotein (59) and in calcification of calcifying vascular cells induced by tumor necrosis factor-{alpha} (60). Similarly, increased activity or expression of bone-related proteins has been associated with vascular calcification in atherogenic ApoE-/- mice (61) as well as calcified human vessels (26). However, the expression pattern of these bone markers during VSMC calcification has not yet been identified. As demonstrated in previous studies, the expression of ALP and Col I genes are early differentiation markers of osteoblast development, whereas the expression of the OC gene marks the late stage of differentiation (18-20). Interestingly, we found that the expression of early differentiation markers for osteoblasts ALP and Col I, was sustained even after 2 weeks in calcifying VSMC (data not shown). Such an expression pattern of ALP and Col I is different from the expression pattern of these genes during osteoblastic differentiation of bone marrow stromal cells (52). Thus, our observations indicate that oxidative stress-induced osteogenic differentiation of VSMC is not simply a mirror image of osteogenic differentiation of osteoblasts.

Most importantly, we demonstrated that Runx2, a key transcription factor for osteoblast and chondrocyte differentiation, was required for oxidative stress-induced VSMC calcification. Emerging evidence has linked Runx2 to vascular calcification (16, 24-28). However, it is not known whether the increased expression of Runx2 is a result of VSMC calcification or it causes VSMC calcification and whether Runx2 is essential for VSMC calcification in vitro. With the use of lentivirus-mediated shRNA specifically targeting Runx2, we ablated oxidative stress-induced VSMC calcification in culture (Fig. 4). In addition, we found that transduction of adenovirus encoding Runx2 was sufficient to induce calcification of VSMC (Fig. 5), which is consistent with a previous study showing that adenoviral gene transfer of Runx2 enhanced the osteogenic differentiation of bone marrow stromal cells (44). Notably, the expression of Runx2 mRNA is not affected during BMP-2-induced osteogenic differentiation of primary aortic myofibroblasts (62), indicating different roles of Runx2 in calcification of myofibroblasts induced by BMP-2 and VSMC induced by oxidative stress. These studies indicate that Runx2 plays an essential role in oxidative stress-induced VSMC calcification in vitro, and Runx2 alone is sufficient to induce VSMC calcification.

The molecular mechanism by which Runx2 regulates VSMC calcification is not yet fully understood. Runx2 is required for mesenchymal condensation, differentiation of osteoblast from mesenchymal stem cells, chondrocyte hypertrophy, and vascular invasion of developing skeletons (63). The DNA binding sites of Runx2 have been identified in the genes of major bone matrix proteins including Col I and OC, and Runx2 induces the expression of these genes or activates their promoters in osteoblasts (21, 63). Blocking Runx2 transcriptional activity by a dominant-negative Runx2 has been shown to decrease uremic serum-induced ALP activity and OC expression (28). Consistently, we found that increased expression of ALP, Col I, and OC was associated with increased Runx2 during VSMC calcification (Figs. 2 and 3), and inhibition of Runx2 expression and activity was associated with decreased expression of ALP and Col I (Figs. 4 and 6).

On the other hand, we found that H2O2 inhibited the expression of VSMC markers, which is consistent with previous studies demonstrating that down-regulation of VSMC markers during calcification (16). However, a previous study reported transforming growth factor β1 (TGF-β1)-induced H2O2 production, which contributes to TGF-β1-induced VSMC marker gene expression in 10T1/2 cells (64). The different cell type and different stimuli may explain the discrepancy between the two studies. The 10T1/2 cells are multipotent embryonic fibroblasts that express minimal or undetectable amounts of SM22{alpha} and {alpha}-SMA, which was confirmed by Sato et al. (64). In addition, the amount of H2O2 was not measured, and the direct effect of H2O2 on the expression of VSMC markers was not determined. In our study we determined the direct effect of H2O2 on the expression of VSMC markers with well differentiated VSMC, which express high levels of VSMC markers.


Figure 6
View larger version (80K):
[in this window]
[in a new window]

  		FIGURE 6.
PI3K/AKT signaling mediates oxidative stress-induced Runx2 activation and VSMC calcification. A, the effect of oxidative stress on the phosphorylation of ERK, PLC{gamma}, and AKT was determined in VSMC exposed to 0.4 mM H2O2 in osteogenic media by Western blot analysis. Representative results from two independent experiments in duplicate are shown. B, the effect of PI3K inhibitor (LY294002) and AKT inhibitor (AKT Inhibitor IV) on the oxidative stress-induced VSMC calcification was determined by von Kossa staining. VSMC were pretreated with LY294002 (25 µM) or AKT inhibitor IV (0.1 µM) for 30 min and then exposed to 0.4 mM H2O2 in osteogenic media. Treatment was repeated every 3 days, and cells were treated for 2 weeks. Representative results from two independent experiments are shown. The effect of inhibitors on the phosphorylation of AKT was determined by Western blot analysis in VSMC pretreated with LY294002 (25 µM) or AKT inhibitor IV (0.1 µM) for 30 min and then exposed to 0.4 mM H2O2 for 15 min in osteogenic media. C, the effect of AKT inhibitor on the expression of Runx2, ALP, Col IA1, and {alpha}-SMA was determined by RT-PCR. VSMC were pretreated with AKT inhibitor IV (0.1 µM) for 30 min and then exposed to 0.4 mM H2O2 in osteogenic media. Treatment was repeated every 3 days for 2 weeks. Representative RT-PCR pictures of two independent experiments are shown. D, the effect of AKT inhibitor on the Runx2 transactivity in VSMC under oxidative stress was determined with a luciferase reporter. VSMC were transiently co-transfected with p6xRunxLuc and a plasmid expressing Renilla luciferase as an internal control reporter. 24 h after transfection cells were pretreated with AKT inhibitor IV (0.1 µM) for 30 min and then exposed to 0.4 mM H2O2 for 48 h. The reporter luciferase activity was determined and normalized to the Renilla luciferase activity using Dual-Luciferase Reporter assay system. Results from three independent experiments in duplicate are shown (*, p < 0.01). E, the effect of oxidative stress or AKT inhibition on VSMC apoptosis was determined by annexin V flow cytometry analysis. VSMC were pretreated with AKT inhibitor (AKTi) IV (0.1 µM) for 30 min and then exposed to 0.4 mM H2O2 for 3 days. The number in each quadrant represents the percent of total cells. Early and late apoptotic cells are in the lower and upper right hand quadrants, respectively. PI, propidium iodine. Representative results from two independent experiments are shown.

 
The mechanism by which H2O2 induces down-regulation of VSMC markers is not fully understood. We found that expression of myocardin and SRF, the key regulators for VSMC markers, was inhibited during H2O2-induced VSMC calcification, which may contribute to the down-regulation of VSMC markers (Fig. 4C). A recent study found that overexpression of Runx2 in C3H10T1/2 mesenchymal cells repressed myocardin-induced SMC gene expression, whereas overexpression of myocardin induced a greater level of SMC marker gene expression in the Runx2 knockdown cells (65). Furthermore, a direct interaction of Runx2 with SRF that disrupts the formation of myocardin and SRF complex was shown to mediate the effect of Runx2 on SMC marker gene expression (65). In our system, H2O2-inhibited expression of VSMC markers was not restored by Runx2 knockdown, indicating that additional signaling pathways independent of Runx2 are involved. Apparently, inhibition of the expression of the VSMC transcription factors, myocardin and SRF, contributes to the down-regulation of VSMC markers by H2O2.

We further determined the molecular signals involved in oxidative stress-induced VSMC calcification. H2O2 can induce downstream signaling by both autocrine and paracrine mechanisms. Exogenous H2O2 can induce production of endogenous H2O2 by activating cellular NAD(P)H oxidase (66), which in turn activates intracellular signaling, including c-Src, PI3K, ERK, AKT, c-Jun N-terminal kinases (JNK), big MAPK (ERK5), and p38 MAPK (8, 9). We found that H2O2-activated PI3K/AKT signaling, but not ERK or PLC{gamma} signaling, was required for H2O2-induced VSMC calcification (Fig. 6). Exogenous H2O2 has been shown to activate PI3K signaling in various cell types (67, 68), probably via a mechanism by which H2O2 induces tyrosine phosphorylation of p110 (PI3K subunit) and enhances PI3K membrane recruitment to its substrate site, thereby enabling PI3K to maximize its catalytic efficiency (67). H2O2-activated PI3K can lead to activation of AKT (69), a transducer of PI3K signaling that activates multiple cellular signaling pathways. PI3K/AKT signaling has been implicated as a critical pathway for the in vitro differentiation of skeletal component cells, including chondrocytes, osteoblasts, myoblasts, and adipocytes (70). Furthermore, bone development is severely delayed in mice lacking both Akt1 and Akt2, supporting an important role of AKT signaling in the differentiation of skeletal cells (71). By contrast, activation of PI3K signaling by insulin-like growth factor-I appears to inhibit differentiation and mineralization of calcifying vascular cells (72), indicating that PI3K signaling activated by different stimuli may have different effects on osteogenic differentiation in different cell types. In addition, we have found that H2O2-induced activation of PI3K/AKT signaling regulated Runx2 expression and transactivity as well as the expression of bone markers during VSMC calcification. These results are consistent with observations that PI3K/AKT signaling increases DNA binding of Runx2 and transcriptional activation by Runx2 during osteoblast and chondrocyte differentiation (70).

Taken together, our results reveal a critical role of the PI3K/AKT/Runx2 signaling axis in regulating H2O2-induced VSMC calcification. We found the expression of Runx2 is essential during oxidative stress-induced osteogenic differentiation and calcification of VSMC. Furthermore, enhanced expression of Runx2 is sufficient to induce VSMC calcification. Activation of AKT signaling appears to mediate oxidative stress-induced Runx2 expression and activity during VSMC calcification. Our findings provide important molecular insights into the role of Runx2 and PI3K/AKT signaling in the regulation of vascular calcification and may have important clinical implications in designing successful therapy to prevent and treat diseases associated with vascular calcification.


   FOOTNOTES
 
* This work was supported, in whole or in part, by National Institutes of Health Predoctoral Training Grant T32 (to C. H. B.). This work was also supported by a Scientist Develop Grant from American Heart Association (National Center) (to Y. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Supported by National Institutes of Health Grant R01 AG030228. Back

2 Supported by a Veterans Affairs Merit Review Award. Back

3 Supported by National Institutes of Health Grant R01 HL58031. Back

4 To whom correspondence should be addressed: 1530 3rd Ave South, 533 LHRB, Birmingham, AL 35294. Tel.: 205-996-6293; Fax: 205-975-9927; E-mail: ybchen{at}uab.edu.

5 The abbreviations used are: VSMC, vascular smooth muscle cells; ROS, reactive oxygen species; ALP, alkaline phosphatase; Col I, type I collagen; OC, osteocalcin; Runx2, runt-related transcription factor 2; {alpha}-SMA, {alpha}-smooth muscle actin; SRF, serum response factor; PI3K, phosphatidylinositol 3-kinase; shRNA, short hairpin RNA; Ad-Runx2, adenovirus encoding murine wild-type Runx2; ERK, extracellular-regulated kinase; PLC, phospholipase C; p-, phosphorylated; GFP, green fluorescent protein; MAPK, mitogen-activated protein kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Back


   ACKNOWLEDGMENTS
 
We thank the Genetically Defined Microbe and Expression Core of the Mucosal HIV and Immunobiology Center and Center for Metabolic Bone Disease (National Institutes of Health Grant P30 AR046031 to J. M. M.) for technical support. We also thank Dr. Linda Demer (UCLA) for helpful discussion.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Trion, A., and van der, L. A. (2004) Am. Heart J. 147, 808-814[CrossRef][Medline] [Order article via Infotrieve]
  2. Hayashi, K., Nakamura, S., Nishida, W., and Sobue, K. (2006) Mol. Cell. Biol. 26, 9456-9470[Abstract/Free Full Text]
  3. Witztum, J. L. (1994) Lancet 344, 793-795[CrossRef][Medline] [Order article via Infotrieve]
  4. Schmidt, A. M., Hori, O., Chen, J. X., Li, J. F., Crandall, J., Zhang, J., Cao, R., Yan, S. D., Brett, J., and Stern, D. (1995) J. Clin. Investig. 96, 1395-1403[Medline] [Order article via Infotrieve]
  5. Scheidegger, K. J., Butler, S., and Witztum, J. L. (1997) J. Biol. Chem. 272, 21609-21615[Abstract/Free Full Text]
  6. Zoccali, C., Mallamaci, F., and Tripepi, G. (2004) J. Am. Soc. Nephrol. 15, Suppl. 1, 77-80[CrossRef]
  7. Stocker, R., and Keaney, J. F., Jr. (2004) Physiol. Rev. 84, 1381-1478[Abstract/Free Full Text]
  8. Martindale, J. L., and Holbrook, N. J. (2002) J. Cell. Physiol. 192, 1-15[CrossRef][Medline] [Order article via Infotrieve]
  9. Cai, H. (2005) Cardiovasc. Res. 68, 26-36[Abstract/Free Full Text]
  10. Ardanaz, N., and Pagano, P. J. (2006) Exp. Biol. Med. (Maywood) 231, 237-251[Abstract/Free Full Text]
  11. Gutierrez, J., Ballinger, S. W., Darley-Usmar, V. M., and Landar, A. (2006) Circ. Res. 99, 924-932[Abstract/Free Full Text]
  12. Keaney, J. F., Jr., Xu, A., Cunningham, D., Jackson, T., Frei, B., and Vita, J. A. (1995) J. Clin. Investig. 95, 2520-2529[Medline] [Order article via Infotrieve]
  13. Carew, T. E., Schwenke, D. C., and Steinberg, D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 7725-7729[Abstract/Free Full Text]
  14. Cseko, C., Bagi, Z., and Koller, A. (2004) J. Appl. Physiol. 97, 1130-1137[Abstract/Free Full Text]
  15. Iyemere, V. P., Proudfoot, D., Weissberg, P. L., and Shanahan, C. M. (2006) J. Intern. Med. 260, 192-210[CrossRef][Medline] [Order article via Infotrieve]
  16. Steitz, S. A., Speer, M. Y., Curinga, G., Yang, H. Y., Haynes, P., Aebersold, R., Schinke, T., Karsenty, G., and Giachelli, C. M. (2001) Circ. Res. 89, 1147-1154[Abstract/Free Full Text]
  17. Collin-Osdoby, P. (2004) Circ. Res. 95, 1046-1057[Abstract/Free Full Text]
  18. Stinson, R. A., and Hamilton, B. A. (1994) Clin. Biochem. 27, 49-55[CrossRef][Medline] [Order article via Infotrieve]
  19. Pagani, F., Francucci, C. M., and Moro, L. (2005) J. Endocrinol. Investig. 28, 8-13[Medline] [Order article via Infotrieve]
  20. Gallop, P. M., Lian, J. B., and Hauschka, P. V. (1980) N. Engl. J. Med. 302, 1460-1466[Medline] [Order article via Infotrieve]
  21. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997) Cell 89, 747-754[CrossRef][Medline] [Order article via Infotrieve]
  22. Inada, M., Yasui, T., Nomura, S., Miyake, S., Deguchi, K., Himeno, M., Sato, M., Yamagiwa, H., Kimura, T., Yasui, N., Ochi, T., Endo, N., Kitamura, Y., Kishimoto, T., and Komori, T. (1999) Dev. Dyn. 214, 279-290[CrossRef][Medline] [Order article via Infotrieve]
  23. Lian, J. B., Javed, A., Zaidi, S. K., Lengner, C., Montecino, M., van Wijnen, A. J., Stein, J. L., and Stein, G. S. (2004) Crit. Rev. Eukaryot. Gene Expression 14, 1-41[Medline] [Order article via Infotrieve]
  24. Engelse, M. A., Neele, J. M., Bronckers, A. L., Pannekoek, H., and de Vries, C. J. (2001) Cardiovasc. Res. 52, 281-289[Abstract/Free Full Text]
  25. Aikawa, E., Nahrendorf, M., Sosnovik, D., Lok, V. M., Jaffer, F. A., Aikawa, M., and Weissleder, R. (2007) Circulation 115, 377-386[Abstract/Free Full Text]
  26. Tyson, K. L., Reynolds, J. L., McNair, R., Zhang, Q., Weissberg, P. L., and Shanahan, C. M. (2003) Arterioscler. Thromb. Vasc. Biol. 23, 489-494[Abstract/Free Full Text]
  27. Mori, K., Shioi, A., Jono, S., Nishizawa, Y., and Morii, H. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 2112-2118[Abstract/Free Full Text]
  28. Chen, N. X., Duan, D., O'Neill, K. D., Wolisi, G. O., Koczman, J. J., Laclair, R., and Moe, S. M. (2006) Kidney Int. 70, 1046-1053[CrossRef][Medline] [Order article via Infotrieve]
  29. Chen, Y., Kelm, R. J., Jr., Budd, R. C., Sobel, B. E., and Schneider, D. J. (2004) J. Cell. Biochem. 92, 178-188[CrossRef][Medline] [Order article via Infotrieve]
  30. Chen, Y., Budd, R. C., Kelm, R. J., Jr., Sobel, B. E., and Schneider, D. J. (2006) Arterioscler. Thromb. Vasc. Biol. 26, 1777-1783[Abstract/Free Full Text]
  31. Wada, T., McKee, M. D., Steitz, S., and Giachelli, C. M. (1999) Circ. Res. 84, 166-178[Abstract/Free Full Text]
  32. Sprague, S. M., Krieger, N. S., and Bushinsky, D. A. (1993) Am. J. Physiol. 264, F882-F890[Medline] [Order article via Infotrieve]
  33. Qu, Q., Perala-Heape, M., Kapanen, A., Dahllund, J., Salo, J., Vaananen, H. K., and Harkonen, P. (1998) Bone (NY) 22, 201-209
  34. Nakamura, A., Ly, C., Cipetic, M., Sims, N. A., Vieusseux, J., Kartsogiannis, V., Bouralexis, S., Saleh, H., Zhou, H., Price, J. T., Martin, T. J., Ng, K. W., Gillespie, M. T., and Quinn, J. M. (2007) Bone (NY) 40, 305-315
  35. Cool, S. M., and Nurcombe, V. (2005) Stem Cells Dev. 14, 632-642[CrossRef][Medline] [Order article via Infotrieve]
  36. Ishida, K., and Yamaguchi, M. (2005) Int. J. Mol. Med. 16, 689-694[Medline] [Order article via Infotrieve]
  37. Nakagami, H., Nakagawa, N., Takeya, Y., Kashiwagi, K., Ishida, C., Hayashi, S., Aoki, M., Matsumoto, K., Nakamura, T., Ogihara, T., and Morishita, R. (2006) Hypertension 48, 112-119[Abstract/Free Full Text]
  38. Ueyama, T., Kasahara, H., Ishiwata, T., Nie, Q., and Izumo, S. (2003) Mol. Cell. Biol. 23, 9222-9232[Abstract/Free Full Text]
  39. Miano, J. M., Ramanan, N., Georger, M. A., Mesy Bentley, K. L., Emerson, R. L., Balza, R. O., Jr., Xiao, Q., Weiler, H., Ginty, D. D., and Misra, R. P. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 17132-17137[Abstract/Free Full Text]
  40. Wesche-Soldato, D. E., Chung, C. S., Lomas-Neira, J., Doughty, L. A., Gregory, S. H., and Ayala, A. (2005) Blood 106, 2295-2301[Abstract/Free Full Text]
  41. Ducy, P., and Karsenty, G. (1995) Mol. Cell. Biol. 15, 1858-1869[Abstract]
  42. Chen, Y., Billadello, J. J., and Schneider, D. J. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 2696-2701[Abstract/Free Full Text]
  43. Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., and Kappes, J. C. (2000) Mol. Ther. 2, 47-55[CrossRef][Medline] [Order article via Infotrieve]
  44. Zhao, Z., Zhao, M., Xiao, G., and Franceschi, R. T. (2005) Mol. Ther. 12, 247-253[CrossRef][Medline] [Order article via Infotrieve]
  45. Chen, Y., Xu, J., Jhala, N., Pawar, P., Zhu, Z. B., Ma, L., Byon, C. H., and McDonald, J. M. (2006) Am. J. Pathol. 169, 1833-1842[Abstract/Free Full Text]
  46. Fernandes, R., Ramalho, J., and Pereira, P. (2006) Mol. Vis. 12, 1526-1535[Medline] [Order article via Infotrieve]
  47. Towler, D. A., Shao, J. S., Cheng, S. L., Pingsterhaus, J. M., and Loewy, A. P. (2006) Ann. N. Y. Acad. Sci. 1068, 327-333[CrossRef][Medline] [Order article via Infotrieve]
  48. Bostrom, K., Watson, K. E., Stanford, W. P., and Demer, L. L. (1995) Am. J. Cardiol. 75, 88-91[CrossRef][Medline] [Order article via Infotrieve]
  49. Yet, S. F., Layne, M. D., Liu, X., Chen, Y. H., Ith, B., Sibinga, N. E., and Perrella, M. A. (2003) FASEB J. 17, 1759-1761[Abstract/Free Full Text]
  50. Clarke, M., and Bennett, M. (2006) Am. J. Nephrol. 26, 531-535[CrossRef][Medline] [Order article via Infotrieve]
  51. Mody, N., Parhami, F., Sarafian, T. A., and Demer, L. L. (2001) Free Radic. Biol. Med. 31, 509-519[CrossRef][Medline] [Order article via Infotrieve]
  52. Huang, J. C., Sakata, T., Pfleger, L. L., Bencsik, M., Halloran, B. P., Bikle, D. D., and Nissenson, R. A. (2004) J. Bone Miner. Res. 19, 235-244[CrossRef][Medline] [Order article via Infotrieve]
  53. Lee, D. H., Lim, B. S., Lee, Y. K., and Yang, H. C. (2006) Cell Biol. Toxicol. 22, 39-46[CrossRef][Medline] [Order article via Infotrieve]
  54. Liberman, M., Bassi, E., Martinatti, M. K., Lario, F. C., Wosniak, J. J., Pomerantzeff, P. M., and Laurindo, F. R. (2008) Arterioscler. Thromb. Vasc. Biol. 28, 463-470[Abstract/Free Full Text]
  55. Arai, M., Shibata, Y., Pugdee, K., Abiko, Y., and Ogata, Y. (2007) IUBMB Life 59, 27-33[CrossRef][Medline] [Order article via Infotrieve]
  56. Banks, L. M., Lees, B., MacSweeney, J. E., and Stevenson, J. C. (1994) Eur. J. Clin. Investig. 24, 813-817[Medline] [Order article via Infotrieve]
  57. Johnson, R. C., Leopold, J. A., and Loscalzo, J. (2006) Circ. Res. 99, 1044-1059[Abstract/Free Full Text]
  58. Davies, J. D., Carpenter, K. L., Challis, I. R., Figg, N. L., McNair, R., Proudfoot, D., Weissberg, P. L., and Shanahan, C. M. (2005) J. Biol. Chem. 280, 3911-3919[Abstract/Free Full Text]
  59. Proudfoot, D., Davies, J. D., Skepper, J. N., Weissberg, P. L., and Shanahan, C. M. (2002) Circulation 106, 3044-3050[Abstract/Free Full Text]
  60. Tintut, Y., Patel, J., Parhami, F., and Demer, L. L. (2000) Circulation 102, 2636-2642[Abstract/Free Full Text]
  61. Rattazzi, M., Bennett, B. J., Bea, F., Kirk, E. A., Ricks, J. L., Speer, M., Schwartz, S. M., Giachelli, C. M., and Rosenfeld, M. E. (2005) Arterioscler. Thromb. Vasc. Biol. 25, 1420-1425[Abstract/Free Full Text]
  62. Cheng, S. L., Shao, J. S., Charlton-Kachigian, N., Loewy, A. P., and Towler, D. A. (2003) J. Biol. Chem. 278, 45969-45977[Abstract/Free Full Text]
  63. Komori, T. (2002) J. Cell. Biochem. 87, 1-8[Medline] [Order article via Infotrieve]
  64. Sato, M., Kawai-Kowase, K., Sato, H., Oyama, Y., Kanai, H., Ohyama, Y., Suga, T., Maeno, T., Aoki, Y., Tamura, J., Sakamoto, H., Nagai, R., and Kurabayashi, M. (2005) Arterioscler. Thromb. Vasc. Biol. 25, 341-347[Abstract/Free Full Text]
  65. Tanaka, T., Sato, H., Doi, H., Yoshida, C. A., Shimizu, T., Matsui, H., Yamazaki, M., Akiyama, H., Kawai-Kowase, K., Iso, T., Komori, T., Arai, M., and Kurabayashi, M. (2008) Mol. Cell. Biol. 28, 1147-1160[Abstract/Free Full Text]
  66. Li, W. G., Miller, F. J., Jr., Zhang, H. J., Spitz, D. R., Oberley, L. W., and Weintraub, N. L. (2001) J. Biol. Chem. 276, 29251-29256[Abstract/Free Full Text]
  67. Qin, S., and Chock, P. B. (2003) Biochemistry 42, 2995-3003[CrossRef][Medline] [Order article via Infotrieve]
  68. Lee, M. H., Kim, Y. J., Yoon, W. J., Kim, J. I., Kim, B. G., Hwang, Y. S., Wozney, J. M., Chi, X. Z., Bae, S. C., Choi, K. Y., Cho, J. Y., Choi, J. Y., and Ryoo, H. M. (2005) J. Biol. Chem. 280, 35579-35587[Abstract/Free Full Text]
  69. Lahair, M. M., Howe, C. J., Rodriguez-Mora, O., McCubrey, J. A., and Franklin, R. A. (2006) Antioxid. Redox Signal. 8, 1749-1756[CrossRef][Medline] [Order article via Infotrieve]
  70. Fujita, T., Azuma, Y., Fukuyama, R., Hattori, Y., Yoshida, C., Koida, M., Ogita, K., and Komori, T. (2004) J. Cell Biol. 166, 85-95[Abstract/Free Full Text]
  71. Peng, X. D., Xu, P. Z., Chen, M. L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., Coleman, K. G., and Hay, N. (2003) Genes Dev. 17, 1352-1365[Abstract/Free Full Text]
  72. Radcliff, K., Tang, T. B., Lim, J., Zhang, Z., Abedin, M., Demer, L. L., and Tintut, Y. (2005) Circ. Res. 96, 398-400[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
M. Mizobuchi, D. Towler, and E. Slatopolsky
Vascular Calcification: The Killer of Patients with Chronic Kidney Disease
J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. D. Miller, R. M. Weiss, K. M. Serrano, R. M. Brooks II, C. J. Berry, K. Zimmerman, S. G. Young, and D. D. Heistad
Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice
Circulation, May 26, 2009; 119(20): 2693 - 2701.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
L. L. Demer, A. P. Sage, and Y. Tintut
Nanoscale Architecture in Atherosclerotic Calcification
Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 1882 - 1884.
[Full Text] [PDF]

Home page
 CirculationHome page
R. C. Shroff, R. McNair, N. Figg, J. N. Skepper, L. Schurgers, A. Gupta, M. Hiorns, A. E. Donald, J. Deanfield, L. Rees, et al.
Dialysis Accelerates Medial Vascular Calcification in Part by Triggering Smooth Muscle Cell Apoptosis
Circulation, October 21, 2008; 118(17): 1748 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. A. Towler
Oxidation, Inflammation, and Aortic Valve Calcification: Peroxide Paves an Osteogenic Path
J. Am. Coll. Cardiol., September 2, 2008; 52(10): 851 - 854.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/22/15319    most recent
M800021200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Byon, C. H.
Right arrow Articles by Chen, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byon, C. H.
Right arrow Articles by Chen, Y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement